Scenic employs a proprietary target discovery technology called Cell-Seq. It uses special human cells that carry only a single copy of every gene, instead of the usual two. Individual genes in billions of these cells are inactivated so that nearly every gene in the genome is inactivated often several thousands of times. From this very large “library” of mutant cells, millions of cells with a cellular phenotype of interest, such as a disease-associated process, are isolated and analyzed by the latest DNA sequencing technology. Bioinformatics analysis then identifies every gene that modifies the cellular phenotype, including novel drug targets. The approach is used on healthy and diseased cells to unearth disease-specific genetic modifiers, including disease suppressors.
1: Brockmann M, et al. Nature. 2017 PMID:28562590
2: Mezzadra R, et al. Nature. 2017 PMID:28813410
3: Staring J et al. Nature. 2017 PMID: 28077878.
4: Nieuwenhuis J, et al. Science. 2017 PMID: 29146869
5: Blomen VA, Science. 2015 PMID: 26472760.